The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment.
One of the oldest American pharmaceutical and consumer...
Despite the success of Kenvue’s IPO, Johnson & Johnson remains under allegations that some of its talc products are cancerous.
Kenvue, the consumer-health spinoff announced by Johnson & Johnson (NYSE: JNJ) last year, has become the largest US IPO...
Pharmaceutical powerhouse J&J expects to price its Kenvue IPO shares at $20 to $23 for a potential $40 billion company valuation.Â
Johnson & Johnson (NYSE: JNJ) plans to price shares of its upcoming Kenvue Inc IPO between $20 and $23. The initial...
